GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Other Current Payables

JW (Cayman) Therapeutics Co (HKSE:02126) Other Current Payables : HK$83.5 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Other Current Payables?

JW (Cayman) Therapeutics Co's Other Current Payables for the quarter that ended in Dec. 2023 was HK$83.5 Mil.

JW (Cayman) Therapeutics Co's quarterly Other Current Payables declined from Dec. 2022 (HK$125.9 Mil) to Jun. 2023 (HK$63.5 Mil) but then increased from Jun. 2023 (HK$63.5 Mil) to Dec. 2023 (HK$83.5 Mil).

JW (Cayman) Therapeutics Co's annual Other Current Payables declined from Dec. 2021 (HK$155.4 Mil) to Dec. 2022 (HK$125.9 Mil) and declined from Dec. 2022 (HK$125.9 Mil) to Dec. 2023 (HK$83.5 Mil).


JW (Cayman) Therapeutics Co Other Current Payables Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Other Current Payables Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Payables
Get a 7-Day Free Trial 83.47 95.53 155.42 125.94 83.48

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 155.42 115.89 125.94 63.54 83.48

JW (Cayman) Therapeutics Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


JW (Cayman) Therapeutics Co Other Current Payables Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Executives
Li Dan 2202 Interest of your spouse
Li Yiping James 2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd. 2501 Other
Bristol-myers Squibb Company 2201 Interest of corporation controlled by you
Celgene Corporation 2201 Interest of corporation controlled by you
Juno Therapeutics, Inc. 2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd. 2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines